ReviewMycopathologia2019
Attack, Defend and Persist: How the Fungal Pathogen Candida auris was Able to Emerge Globally in Healthcare Environments.
Review in Mycopathologia, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
55 citing papers in PubMed, 94 citations in OpenAlex.
- Review
- Protein-related hydrophobicity differences among strains belonging toMicrobiology spectrum · 2026Article
- Candidozyma auris in The Netherlands: No Evidence of Nosocomial Transmission Supported by Effective Infection Control Policies.Mycopathologia · 2026Article
- Repositioning Antimicrobial Peptides Against WHO-Priority Fungi.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Review
- Genomic Dynamics of the EmergentOpen forum infectious diseases · 2025Article
- Biocide, antifungal susceptibility and virulence characteristics of Clade 1 Candidozyma auris strains.Annals of clinical microbiology and antimicrobials · 2025Article
- Expansion of the Candidozyma haemuli Species Complex - The Novel Species Candidozyma molenica, Isolated from Clinical and Environmental Sources.Mycopathologia · 2025Article
- Synthesis of New Glycometronidazole Compounds With Antifungal and Antifungal Biofilm Activity.Chemical biology & drug design · 2025Article
- Protease production by Serratia liquefaciens NRC1 using fish gut waste as a sustainable approach to antimicrobial peptide generation and combating Candida auris acquired resistance.Microbial cell factories · 2025Article
- Article
- Virulence profile of pathogenic yeasts from snakes: Alternative ways for antifungal strategies.PloS one · 2025Article
- Research advances and public health strategies in China on WHO priority fungal pathogens.Mycology · 2025Review
- Variable sensitivity of clinical Candida auris strains to Biocides: implications for infection control in Healthcare Settings.BMC microbiology · 2024Article
- Functional redundancy in Candida auris cell surface adhesins crucial for cell-cell interaction and aggregation.Nature communications · 2024Article
- Transcriptome Analysis of Human Dermal Cells Infected with Candida auris Identified Unique Pathogenesis/Defensive Mechanisms Particularly Ferroptosis.Mycopathologia · 2024Article
- Functional Redundancy inResearch square · 2024Article
- Functional Redundancy inbioRxiv : the preprint server for biology · 2024Article
- The Gordian Knot ofPathogens (Basel, Switzerland) · 2023Review
- SevereJournal of intensive medicine · 2023Review
- AFM evaluation of a humanized recombinant antibody affectingRSC advances · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Within a decade after its first description, the multidrug-resistant yeast Candida auris has emerged globally as a nosocomial pathogen causing difficult to control outbreaks. This, together with the alarmingly high mortality rate of up to 66% associated with C. auris candidemia, calls for a better understanding of its virulence traits and routes of transmission. Unlike other clinically relevant Candida species, C. auris seems to have the unique ability to be easily transmitted between patients. Although initially thought to express fewer virulence traits than Candida albicans, recent genomic insights suggest C. auris to possess these traits to a much more similar extent. This review highlights the virulence traits C. auris expresses to attack the host, defend itself against antimicrobial agents and to persist within the healthcare environment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.